Corion Biotech Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$161K
- Investors
-
4
Corion Biotech General Information
Description
Developer of innovative therapies designed to enhance women's health. The company's technology is based on a specific cell population derived from the human term placenta and develops innovative therapeutic solutions for women's health, enabling medical practitioners to maintain the effectiveness of cell therapy avoiding the risk of direct administration of living allogenic cells.
Contact Information
Website
www.corionbiotech.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Devices and Supplies
Primary Office
- Via G. Quarello 15/a
- 10135 Turin(Torino)
- Italy
+39 347 000 0000
Corion Biotech Timeline
Corion Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Seed Round | 15-Jun-2023 | $161K | 00.000 | Completed | Pre-Clinical Trials | |
| 3. Seed Round | 31-Jul-2020 | 00.000 | 00.000 | Completed | Generating Revenue | |
| 2. Early Stage VC | 01-Mar-2015 | $170K | $170K | Completed | Startup | |
| 1. Accelerator/Incubator | Completed | Startup |
Corion Biotech Patents
Corion Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2886946-C | Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour | Active | 02-Oct-2012 | 000000000 | |
| CA-2886946-A1 | Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour | Active | 02-Oct-2012 | 000000000 | |
| EP-2903624-A1 | Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour | Active | 02-Oct-2012 | 000000000 | |
| EP-2903624-B1 | Preeclamptic placental mesenchymal stem cell conditioned medium for use in the treatment of a tumour | Active | 02-Oct-2012 | 000000000 | |
| ES-2720232-T3 | Preeclamptic placental mesenchymal stem cell conditioning medium for use in the treatment of a tumor | Active | 02-Oct-2012 | A61K35/28 |
Corion Biotech Executive Team (3)
Corion Biotech Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alessandro Rolfo Ph.D | Corion Biotech | Co-Founder, Chief Scientific Officer & Board Member | 000 0000 |
| Tullia Todros MD | Corion Biotech | Co-Founder, Chief Medical Officer & Board Member | 000 0000 |
Corion Biotech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Corion Biotech Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Liftt | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Fondazione Carlo Denegri Social Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| IP Investimenti e Partecipazioni | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| 2i3T | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |